SYBLEU Inc
SYBE
Other OTC0.06
USD
- -
- -
SYBLEU Inc
SYBE
(Other OTC)
Recent
price
0.06
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Sybleu Inc. Sybleu Inc. (SYBE) is a biotechnology company focused on the acquisition, licensing, and development of regenerative medical applications, therapies for human and animal health, medical devices, and clinical diagnostics; its core products and services encompass small molecule drug therapies targeting companion animal ailments such as cancer and arthritis via patent-protected compounds under US patents 10,472,351 B2 and 11,377,442 B2, an exclusive worldwide license for an AI/ML engine from DYO Biotechnologies Pty Ltd to predict novel chemical structures and accelerate drug development, cell transplant intellectual property, and veterinary therapeutics, diagnostics, and devices developed up to Phase II clinical trials prior to licensing, sale, or advancement to Phase III. The company operates primarily in the pharmaceuticals and biotech sector, serving human and veterinary markets with a strategy centered on intellectual property acquisition and strategic partnerships to expedite technologies to market. Founded in 2020 and headquartered in Bronx, New York, Sybleu Inc. functions as a subsidiary of Worldwide Holdings, LLC as of April 2024 following its acquisition of a 58.5% stake from prior executives Joseph Vaini and Harry Lander. Recent developments include the June 2023 exclusive licensing of the AI/ML small molecule drug design engine to enhance its pipeline efficiency and a July 2023 purchase of a 50% stake in patent-protected small molecule compounds from Zander Biologics for joint veterinary commercialization, with each party sharing revenues and expenses equally and a $300,000 promissory note due June 2025. These initiatives underscore Sybleu's emphasis on integrating advanced computational tools with targeted IP to address unmet needs in oncology and inflammatory conditions for companion animals.
Goldman Small Cap Research Publishes New Research Report on Sybleu, Inc.
Sybleu Inc. Describes Competitive Landscape Around Artificial Intelligence and Machine Learning in Small Molecule Drug Discovery
Sybleu Inc. Purchases Fifty Percent Stake In Patent Protected Small Molecule Therapeutic Compounds, Anticipates Synergy With Recently In-Licensed AI/ML Engine